ocrelizumab

CHEBI:CHEBI_749928

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
1876385
generic_name
ocrelizumab
pharm_class
Humanized [CS]
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
LIQUID
route
INTRAVENOUS
marketing_start_date
20170328
package_marketing_start_date
28-MAR-17
marketing_category
DRUG FOR FURTHER PROCESSING
nui
M0556300
pharm_class_cs
Antibodies, Monoclonal, Humanized [CS]
active_ingredient_strength
55 g/L
labeler_name
Genentech, Inc.
manufacturer_name
Genentech, Inc.
pharm_class_epc
CD20-directed Cytolytic Antibody [EPC]
pharm_class_moa
CD20-directed Antibody Interactions [MoA]
active_ingredient_name
OCRELIZUMAB
unii
A10SJL62JY
product_ndc
67643-7001
spl_id
2370c7af-4125-c175-e063-6394a90ab69d
package_ndc
67643-7001-1
package_description
300 L in 1 TANK (67643-7001-1)
brand_name
OCREVUS
brand_name_base
OCREVUS
application_number
BLA761053
spl_set_id
9da42362-3bb5-4b83-b4bb-b59fd4e55f0d
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class